Methotrexate in primary cutaneous t-cell lymphoma



In this retrospective qualitative study we review the use of Methotrexate therapy in primary cutaneous T Cell lymphoma patients at Westmead Hospital.
Methotrexate is an antimetabolite which inhibits cell cycle division by inhibiting dihydrofolate reductase1. Oral methotrexate has been used in the treatment of cutaneous T-cell lymphomas of various subtypes for many years2. However, there are no clear guidelines regarding the dosing and length of treatment course required to achieve remission. There is also limited data available about the efficacy of methotrexate in primary cutaneous T-cell lymphoma. Our objective was to review our experience of methotrexate use in our patients with cutaneous T-cell lymphoma at Westmead Hospital. We reviewed medical records of patients from 2016 June to 2012 June and identified patients in whom Methotrexate therapy had been used. We describe the effectiveness of this therapy, the side effects that were experienced by the patients, the average dosages that were used and the reasons for discontinuation.
1. 1 Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. Zackheim, Herschel S et al. Journal of the American Academy of Dermatology, Volume 49, Issue 5, 873 - 878
2. 2 Primary cutaneous T-cell lymphoma (mycosis fungoides and S├ęzary syndrome) Jawed, Sarah I. et al. Journal of the American Academy of Dermatology, Volume 70, Issue 2, 223.e1 - 223.e17


Dr. Thevaki Wain